menu
    • menu
    [{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"PureTech Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Protein","year":"2021","type":"Acquisition","leadProduct":"IL-22","moa":"||IL-22 receptor","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alivio Therapeutics \/ PureTech Health","highestDevelopmentStatusID":"4","companyTruncated":"Alivio Therapeutics \/ PureTech Health"},{"orgOrder":0,"company":"Alivio Therapeutics","sponsor":"US Department of Defense","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Funding","leadProduct":"ALV-304","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Alivio Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alivio Therapeutics \/ US Department of Defense","highestDevelopmentStatusID":"4","companyTruncated":"Alivio Therapeutics \/ US Department of Defense"}]

    Find Clinical Drug Pipeline Developments & Deals by Alivio Therapeutics

    Menu

    Alivio Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alivio Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Alivio Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IL-22,Undisclosed

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : PureTech Health

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            PureTech Acquires Remaining Interest in Founded Entity Alivio Therapeutics

                            Details : The Wholly Owned Pipeline will include the addition of LYT-500. LYT-500 contains a unique combination of IL-22 and an anti-inflammatory drug, which is designed to address the two key underlying causes of IBD pathogenesis and progression.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Undisclosed

                            June 16, 2021

                            Lead Product(s) : IL-22,Undisclosed

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : PureTech Health

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alivio Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            Alivio Therapeutics

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ALV-304

                            Therapeutic Area : Gastroenterology

                            Study Phase : Preclinical

                            Sponsor : US Department of Defense

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Alivio Therapeutics Awarded $3.3 Million from U.S. Department of Defense

                            Details : The funds will support Alivio’s preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            October 05, 2020

                            Lead Product(s) : ALV-304

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Preclinical

                            Sponsor : US Department of Defense

                            Deal Size : $3.3 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth